BEZ235

Item no.	M1671-10mg
Manufacturer	AbMole
CASRN	915019-65-7
Amount	10mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	0,9962
Citations	NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. Civallero, et al . Expert Opin Investig Drugs. 2012 Aug 25. PMID: 22920938 . Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1alpha expression by blocking protein translation and increases cell death under hypoxia. Karar, et al . Cancer Biol Ther. 2012 Sep 1,13(11). PMID: 22895065 . Combined PI3K/mTOR and MEK Inhibition Provides Broad Anti-Tumor Activity in Faithful Murine Cancer Models. Roberts, et al . Clin Cancer Res. 2012 Aug 7. PMID: 22872574 . Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection. Lin, et al . J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jul 15,901:9-17. PMID: 22727754 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	NVP-BEZ235, Dactolisib
Similar products	BEZ235, NVP-BEZ235
Available
Molecular Weight	469, 55
Solubility	DMSO 3 mg/mL
Bioactivity information	BEZ235 (NVP-BEZ235) is a potent dual PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1671-10mg-safety-datasheet.pdf